Tag
#HROW
-
2026
-
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
-
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
-
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
-
HROW – 8-K
-
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth